Trial · NCT06325956
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The number of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry. | Samples to be collected once per participant within 7 days of enrollment. | Flow cytometry was used to detect the antigenic antibody reaction between the surface differentiation antigen of lymphocyte membrane and the fluorescently labeled antibody in human peripheral blood, and the unlabeled cells were dissolved. |
| Primary | The percentage of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry. | Samples to be collected once per participant within 7 days of enrollment. | Flow cytometry was used to detect the antigenic antibody reaction between the surface differentiation antigen of lymphocyte membrane and the fluorescently labeled antibody in human peripheral blood, and the unlabeled cells were dissolved. |
| Secondary | Homeostasis model assessment of insulin resistance | Within 7 days of enrollment. | insulin resistance index |
| Secondary | body mass index | Within 7 days of enrollment. | body mass index (kg/m2) |
| Secondary | menstrual frequency | Within 7 days of enrollment. | number of menstruation in a year |
| Secondary | fasting glucose | Within 7 days of enrollment. | fasting glucose (mmol/L) |
| Secondary | fasting insulin | Within 7 days of enrollment. | fasting insulin (mmol/L) |
| Secondary | Total cholesterol | Within 7 days of enrollment. | Total cholesterol (mmol/L) |
| Secondary | Triglycerides | Within 7 days of enrollment. | Triglycerides (mmol/L) |
| Secondary | HDL-c | Within 7 days of enrollment. | HDL-c (mmol/L) |
| Secondary | LDL-c | Within 7 days of enrollment. | LDL-c (mmol/L) |
| Secondary | total testosterone | Within 7 days of enrollment. | total testosterone (nmol/L) |
| Secondary | free testosterone | Within 7 days of enrollment. | free testosterone (nmol/L) |
| Secondary | Sex hormone-binding globulin | Within 7 days of enrollment. | Sex hormone-binding globulin (nmol/L) |
| Secondary | Androstenedione | Within 7 days of enrollment. | Androstenedione (ng/ml) |
| Secondary | Dehydroepiandrosterone | Within 7 days of enrollment. | Dehydroepiandrosterone (ug/dl) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06325956/registered